AK104 plus lenvatinib versus lenvatinib for advanced liver cancer after prior treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a new combination of drugs (an immunotherapy called AK104 plus a targeted therapy called lenvatinib) compared to lenvatinib alone, for people whose liver cancer has grown after they received the standard first-line treatment with atezolizumab and bevacizumab. The goal is to see if combining the two drugs can better control the cancer and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have liver cancer (hepatocellular carcinoma) that cannot be removed with surgery or treated with local procedures, and it must be in an advanced stage (BCLC stage B or C).
- You must have already received a combination of atezolizumab and bevacizumab as your first systemic treatment, and your cancer must have gotten worse during that treatment.
- Your liver function must be relatively good (classified as Child-Pugh Class A), and you should be able to take care of yourself (ECOG performance status 0 or 1).
- You must not have certain other types of liver tumors (like fibrolamellar or sarcomatoid), or cancer that has spread to the brain or the superior mesenteric vein.
- You must not have had bleeding from esophageal varices in the past 6 months, and you cannot have a history of liver transplantation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a new combination of drugs (AK104 and lenvatinib) to a standard liver cancer procedure called TACE is more effective than TACE alone. It is for people whose liver cancer has not spread and cannot be removed by surgery, but who are well enough to receive these treatments.
This trial tests a combination of two immunotherapy drugs for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if this combination can help control the cancer.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.